ChartAlert®

Featured

Hello, India!

This featured post is about ChartAlert, a Real-Time-Enabled and End-of-Day Technical Analysis Advisory, Charting and Scanning Desktop Software

1–2 minutes

ChartAlert® is a Microsoft® Windows® compatible Real-Time-Enabled and End-of-Day Technical Analysis Advisory, Charting and Scanning Desktop Software that complements your trading and investing needs.

ChartAlert features three seamless modules.

1. The Charting module includes Charting and Masks.

2. The Reporting module includes Basic Advisory Content and Market Reports.

3. The Scanning module includes Basic Scanner, Advanced Scanner, RS Matrix & Trend Matrix, Trading Systems Builder and the Backtester.

SIEMENS – Siemens Ltd – Q4 FY26 Earnings Call – 28-May-26

SIEMENS/ Siemens’ topline growth (12–15%) supported by backlog, but margins (9–11%) and cash flow face cyclical headwinds from commodities/FX; structural margin ceiling in DI without localization.

1–2 minutes

Also see: SIEMENS – Siemens Ltd – Q4 FY26 Financial Results – 26-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Commodity/FX volatility persists, partial price pass-through, private CapEx grows 8–10%.
Outcome: EBITDA margin stabilizes at 10–11% (Q6: 9.7%); order backlog supports 12–15% revenue growth. Mobility ramp-up on track; SI margins improve to 16% as commodities stabilize. Working capital remains elevated but manageable.

FINCABLES – Finolex Cables – Q4 FY26 Earnings Call – 29-May-26

FINCABLES/ Finolex Cables’ topline growth hinges on communications scale-up and EHV JV execution; margins depend on preform cost advantages and copper/FX stability; cash flow recovery tied to inventory normalization and supply chain resilience.

1–2 minutes

Also see: FINCABLES – Finolex Cables – Q4 FY26 Financial Results – 28-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Drivers: Middle East conflict lingers but stabilizes, fiber prices moderate, preform plant stabilizes by Q3 FY27 (5-7% cost advantage). EHV JV maintains INR 400-450 crore revenue, communications EBIT margins improve to 7-8%. Electrical segment grows 15% on project demand, but retail remains weak.
Outcome: Revenue +15-18% YoY, EBITDA margins expand 100-120 bps, cash flow improves but lags due to inventory.

CUMMINSIND – Cummins India – Q4 FY26 Earnings Call – 29-May-26

CUMMINSIND/ Cummins India’s topline growth hinges on data center and CPCB IV+ aftermarket; margins depend on commodity pass-through and HHP localization; Distribution remains resilient.

1–2 minutes

Also see: CUMMINSIND – Cummins India – Q4 FY26 Financial Results – 27-May-26

3-Scenario Framework

📊 Base Case (60% Probability)

Data center demand (30–35% of PowerGen) and CPCB IV+ aftermarket drive high single-digit revenue growth in FY27. Commodity pass-through lag and HHP import dependence cap margin expansion at ~50–100bps. Export growth remains flat (geopolitical caution). Distribution grows 15–20% (warranty exits, service packages).

ASIANPAINT – Asian Paints – Q4 FY26 Earnings Call – 29-May-26

ASIANPAINT/ Asian Paints’ topline resilience hinges on rural/urban demand balance and B2B growth; bottomline depends on margin defense via pricing power and backward integration; margins face structural support (premiumization, cost efficiencies) but cyclical pressure (input costs, geopolitics).

1–2 minutes

Also see: ASIANPAINT – Asian Paints – Q4 FY26 Financial Results – 29-May-26

3-Scenario Framework

📊 Base Case (60% Probability)

Key Variables: Commodity inflation stabilizes at current levels; geopolitical risks remain contained; rural demand sustains.
Outcome: 8–10% volume growth, 18–20% PBDIT margins, double-digit PAT growth. Backward integration partially offsets input costs; price hikes stick.

RVNL – Rail Vikas Nigam – Q4 FY26 Earnings Call – 26-May-26

RVNL/ Rail Vikas Nigam’s topline growth is robust (order book-driven), but margins and cash flows hinge on execution discipline and receivables resolution; modeling should prioritize scenario-based EBITDA and working capital sensitivities.

1–2 minutes

Also see: RVNL – Rail Vikas Nigam – Q4 FY26 Financial Results – 25-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Revenue grows 10–12%; EBITDA margins stabilize at 6–7%; receivables collected over 2 years.
Outcome: Cash flow normalizes by H2 FY27; Vande Bharat and BharatNet contribute to revenue from FY28. PAT grows 10–15% YoY.

POWERINDIA – Hitachi Energy India – Q4 FY26 Earnings Call – 26-May-26

POWERINDIA/ Hitachi Energy India’s topline growth is structurally robust (12–20% CAGR), but margins (12–20% EBITDA) hinge on execution and cost pass-through; cash flow resilience depends on working capital discipline.

1–2 minutes

Also see: POWERINDIA – Hitachi Energy India – Q4 FY26 Financial Results – 25-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Drivers: Steady execution of ₹29,555 Cr backlog, 2–3 HVDC projects/year, and data center growth at 5x. Margins stabilize at 15–17% EBITDA as commodity costs offset by price clauses. Revenue CAGR: 12–15% (FY26–FY28).

ASIANPAINT – Asian Paints – Q4 FY26 Financial Results – 29-May-26

Asian Paints’ FY26 delivered margin recovery and record FCF despite just 5% topline growth. Q4 re‑acceleration is positive, but re‑rating hinges on H1FY27 volume growth >8–10% as Birla Opus disruption stabilises. Home décor losses narrowing and international profitability doubling are tailwinds; monitor Q1 volumes and receivables.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 5.0% YoY (₹33,906 Cr → ₹35,584 Cr FY26); Q4 alone surged 10.6% YoY, signalling Q4 acceleration after a sluggish first half.
Decorative paints India (~84% of consolidated revenue) remains the primary driver; international business (+8.9% YoY to ₹3,340 Cr) added meaningful incremental contribution.
Other income jumped 26.4% YoY (₹573 Cr → ₹724 Cr), partly cushioning operating pressure — a non-trivial ₹724 Cr on a ₹35,584 Cr revenue base.

Bottomline

Reported PAT rose 18.4% YoY (₹3,710 Cr → ₹4,395 Cr FY26); Q4 PAT up 69.3% YoY (₹701 Cr → ₹1,185 Cr), aided by the base effect of ₹183 Cr exceptional items in Q4FY25.
Exceptional items (₹158 Cr in FY26 vs. ₹365 Cr in FY25) largely impairments on international/home décor subsidiaries — lower drag this year inflates apparent YoY PAT improvement.
Effective tax rate held steady at ~26.8% (FY26: ₹1,609 Cr on PBT ₹6,003 Cr vs. ~27.3% in FY25).

Margins

PBDIT margin expanded ~110 bps YoY (17.8% → 18.9% on net sales); raw material cost ratio improved — materials consumed fell from ₹15,794 Cr to ₹15,384 Cr despite ~5% revenue growth, implying meaningful gross margin recovery.
Net profit margin (PAT/Revenue from ops): 12.4% FY26 vs. 10.9% FY25 — a clean 150 bps expansion, driven by operating leverage and lower input costs.
Employee costs (+7.8% YoY) and other expenses (+5.2% YoY) grew broadly in line with revenue — cost discipline holding.

Growth Trajectory

FY26 topline growth (5.0%) is the slowest in several years — volume-led growth story partially stalled amid competitive intensity from Birla Opus and muted urban demand.
Q4 re-acceleration (+10.6% revenue, +24.4% PBDIT) is encouraging but must sustain through H1FY27 to confirm a structural recovery rather than base-effect rebound.
Home décor (Kitchen + Bath) remains loss-making at PBIT level (combined ~₹19 Cr loss in FY26 vs. ~₹51 Cr in FY25) — improvement trajectory present but dilutive to consolidated ROCE.

GLENMARK – Glenmark Pharmaceuticals – Q4 FY26 Financial Results – 29-May-26

Glenmark’s FY26 marks inflection — debt‑free, doubled pre‑exceptional profitability, and robust OCF. Risks: +48.5% receivables surge and ₹22,661M exceptional charges cloud earnings quality. If receivables normalize and charges stabilize, ~₹20,873M FCF supports re‑rating; monitor DSO trends, exceptional disclosures, and ₹15,361M non‑current liability build.

1–2 minutes

🔍 Observations

Topline

Net sales surged 27.1% YoY (₹131,458M → ₹167,114M), driven by broad-based geographic expansion and the Ichnos Sciences consolidation effect post-demerger.
Q4FY26 net sales of ₹37,603M grew 16.8% YoY vs Q4FY25’s ₹32,201M, though sequentially softer vs Q3FY26’s ₹38,880M — slight volume moderation at year-end.
Other operating income jumped to ₹2,711M in FY26 vs ₹1,759M in FY25, reflecting licensing/milestone receipts boosting reported revenue quality.

Bottomline

Reported PAT: ₹13,620M in FY26 vs ₹10,471M in FY25 (+30.1% YoY), but exceptional losses of ₹22,661M (vs ₹3,728M prior year) dominate the narrative — pre-exceptional PBT was ₹42,508M vs ₹17,720M (+139.9% YoY), a far stronger underlying picture.
Q4FY26 PAT of ₹3,013M was inflated by negative current tax (refund of ₹301M) — normalized earnings were lower; Q3FY26 PAT of ₹4,032M was cleaner.
Basic EPS: ₹48.26 in FY26 vs ₹37.11 in FY25 — EPS growth understates operational improvement given the drag from escalating exceptional charges.

Margins

EBITDA proxy (pre-exceptional PBT + Finance costs + D&A): ₹42,508M + ₹2,087M + ₹5,735M = ₹50,330M on revenue of ₹169,825M → EBITDA margin ~29.6% in FY26 vs (₹17,720M + ₹2,071M + ₹4,860M) = ₹24,651M on ₹133,217M → 18.5% in FY25. A 1,110 bps margin expansion.
Reported net margin: ₹13,620M / ₹169,825M = 8.0% — depressed by exceptional items; pre-exceptional PBT margin = 25.0%.
Cost of materials + stock-in-trade consumed ₹47,475M (net of inventory changes ₹6,106M) = ₹41,369M effective material cost on ₹167,114M net sales = 24.8% — improved from prior year’s effective ~32.7%.

Growth Trajectory

Revenue CAGR implied (FY25→FY26): +27.1% — sustainable pace uncertain; Ichnos consolidation is a one-time step-up in the base.
Employee costs grew 18.4% YoY (₹30,221M → ₹35,779M) — below revenue growth, indicating early operating leverage.
Other expenses grew 13.6% YoY (₹35,950M → ₹40,848M) — again below revenue growth, reinforcing operating leverage thesis.

BEML – Beml Ltd – Q4 FY26 Financial Results – 29-May-26

BEML’s FY26 shows earnings compression — PAT down >50% on margin erosion, doubled provisions, and ballooning receivables despite revenue growth. CWIP tripling and Metro/Defence/Railways pipeline support thesis, but re‑rating hinges on expense normalization, receivables conversion, and provision reversal. Until OCF/FCF turn positive, execution visibility drives valuation.

1–2 minutes

🔍 Observations

Topline

FY26 revenue grew 8.2% YoY (₹4,02,222L → ₹4,35,053L), modest but consistent; Q4FY26 at ₹1,79,417L surged 8.6% over Q4FY25, confirming H2-heavy execution pattern
Q3FY26 revenue of ₹1,08,327L was unusually weak — sequential collapse of ~40% — pointing to lumpy government order-driven recognition
Other income rose 24% YoY (₹2,373L → ₹2,944L), marginal contributor but directionally positive

Bottomline

FY26 PAT collapsed 51.7% YoY (₹29,252L → ₹14,136L) despite 8.2% revenue growth — a sharp earnings-quality deterioration
Q3FY26 posted a PAT loss of ₹2,238L; Q4FY26 recovered to ₹17,982L, but Q4FY25 PAT was ₹28,755L — Q4 profitability down 37.5% YoY
Effective tax rate distorted by large deferred tax credit of ₹6,965L in FY26 vs. ₹1,161L charge in FY25; underlying cash tax burden (₹12,725L) stayed elevated

Margins

FY26 EBITDA (PBT + Finance Costs + D&A): ₹19,956 + ₹4,539 + ₹8,348 = ₹32,843L on revenue of ₹4,35,053L → EBITDA margin ~7.5%, down from ~13.1% in FY25 (₹40,376 + ₹5,431 + ₹7,134 = ₹52,941L on ₹4,02,222L)
Net margin compressed to 3.2% (₹14,136L / ₹4,35,053L) vs. 7.3% in FY25 — a 410bps contraction
Other expenses surged 38.8% YoY (₹67,558L → ₹93,787L) on only 8.2% revenue growth — the single largest margin erosion driver

Growth Trajectory

Revenue CAGR is low-single-digit; at current trajectory BEML is not a high-growth compounder but an order-execution vehicle dependent on government capex cycles
Provisions rose sharply: current provisions jumped from ₹25,870L to ₹53,259L (+105.9%), signalling warranty, contractual, or contingent liability build-up
Non-current liabilities grew 8.4% (₹1,11,816L → ₹1,21,178L) while equity grew just 1.6% — leverage creeping up structurally

MAXHEALTH – Max Healthcare Institute – Q4 FY26 Earnings Call – 22-May-26

Max Healthcare’s topline growth hinges on non-onco scaling and greenfield execution, while margins face structural pressure from oncology mix shifts and ALOS volatility.

1–2 minutes

Also see: MAXHEALTH – Max Healthcare Institute – Q4 FY26 Financial Results – 21-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Oncology share stabilizes at 21–22% + Gurgaon breakeven in FY28.
Revenue grows 12–15% CAGR (ex-oncology: 15–18%) as digital/international offset oncology drag. EBITDA margins hover at 26–27% due to ALOS/labor cost lags. Free cash flow ~₹1,500 crore/year funds ₹1,200–1,500 crore annual capex, keeping net debt-to-EBITDA <1.2x.